The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a US national sample

被引:101
作者
Krawczyk, Noa [1 ]
Feder, Kenneth A. [1 ]
Saloner, Brendan [1 ]
Crum, Rosa M. [1 ,2 ,3 ]
Kealhofer, Marc [2 ]
Mojtabai, Ramin [1 ,3 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mental Hlth, 624 North Broadway,624 N Broadway,Room 888, Baltimore, MD 21205 USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 1800 Orleans St, Baltimore, MD 21287 USA
关键词
Substance use treatment; Comorbidity; Treatment retention; Mental health integration; Drug treatment; Alcohol treatment; METHADONE-MAINTENANCE TREATMENT; MEDICATION-ASSISTED TREATMENT; MENTAL-HEALTH DISORDERS; ABUSE TREATMENT; TREATMENT RETENTION; TREATMENT OUTCOMES; DUAL DIAGNOSIS; UNITED-STATES; EPIDEMIOLOGIC SURVEY; GENDER-DIFFERENCES;
D O I
10.1016/j.drugalcdep.2017.02.006
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Psychiatric disorders are highly comorbid with substance use disorders and play an important role in their course and recovery. However, the impact of comorbidity on treatment outcomes has not been examined in a U.S. national sample. This study explores the impact of psychiatric comorbidity on treatment completion among individuals admitted to publicly funded substance use treatment facilities across the United States. Methods: Using data on first-time treatment episodes in the U.S. from the Treatment Episode Dataset-Discharges (TEDS-D) for the years 2009-2011, logistic regression was used to assess the association between psychiatric comorbidity and treatment non-completion, and Cox proportional hazards regression was used to assess the association between comorbidity and rate of attrition. Analyses were performed for all substances together and then stratified by primary substance of abuse (alcohol, cannabis, stimulants, or opioids). Results: Of 856,385 client treatment episodes included in our analysis, 28% had a psychiatric comorbidity and 38% did not complete treatment. After adjusting for socio-demographic and treatment characteristics, clients with psychiatric comorbidity had higher odds of not completing treatment relative to those without comorbidity [OR = 1.28 (1.27-1.29)], and had an earlier time to attrition [HR = 1.14 (1.13-1.15)]. Psychiatric comorbidity was most strongly associated with treatment non-completion and rate of attrition in those admitted primarily for alcohol [OR = 1.37 (1.34-1.39); HR = 1.19 (1.17-1.21), respectively]. Conclusions: Individuals with psychiatric comorbidities receiving treatment for substance use disorders face unique challenges that impact their ability to complete treatment. The findings call for further efforts to integrate treatment for psychiatric comorbidities in substance use treatment settings.
引用
收藏
页码:157 / 163
页数:7
相关论文
共 54 条
[21]   Medication-assisted treatment of opiate dependence is gaining favor [J].
Jerry, Jason M. ;
Collins, Gregory B. .
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2013, 80 (06) :345-349
[22]  
Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719
[23]   The epidemiology of dual diagnosis [J].
Kessler, RC .
BIOLOGICAL PSYCHIATRY, 2004, 56 (10) :730-737
[24]   Challenges and Outcomes of Parallel Care for Patients With Co-Occurring Psychiatric Disorder in Methadone Maintenance Treatment [J].
King, Van L. ;
Brooner, Robert K. ;
Peirce, Jessica ;
Kolodner, Ken ;
Kidorf, Michael .
JOURNAL OF DUAL DIAGNOSIS, 2014, 10 (02) :60-67
[25]   Comorbid psychiatric diagnosis predicts three-year outcomes in alcoholics: A posttreatment natural history study [J].
Kranzler, HR ;
DelBoca, FK ;
Rounsaville, BJ .
JOURNAL OF STUDIES ON ALCOHOL, 1996, 57 (06) :619-626
[26]   Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990-2014: A systematic review and meta-analysis [J].
Lai, Harry Man Xiong ;
Cleary, Michelle ;
Sitharthan, Thiagarajan ;
Hunt, Glenn E. .
DRUG AND ALCOHOL DEPENDENCE, 2015, 154 :1-13
[27]   Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community [J].
Levin, FR ;
Evans, SM ;
Vosburg, SK ;
Horton, T ;
Brooks, D ;
Ng, J .
ADDICTIVE BEHAVIORS, 2004, 29 (09) :1875-1882
[28]   Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity [J].
Maremmani, I ;
Zolesi, O ;
Aglietti, M ;
Marini, G ;
Tagliamonte, A ;
Shinderman, M ;
Maxwell, S .
JOURNAL OF ADDICTIVE DISEASES, 2000, 19 (02) :29-41
[29]   Long-term outcomes of treatment-resistant heroin addicts with and without DSM-IV axis 1 psychiatric comorbidity (dual diagnosis) [J].
Maremmani, Icro ;
Pacini, Matteo ;
Lubrano, Sonia ;
Perugi, Giulio ;
Tagliamonte, Alessandro ;
Pani, Pier Paolo ;
Gerra, Gilberto ;
Shinderman, Marc .
EUROPEAN ADDICTION RESEARCH, 2008, 14 (03) :134-142
[30]   Psychiatric Comorbidity and Complications [J].
Mason, Michael J. ;
Aplasca, Alexis ;
Morales-Theodore, Rosa ;
Zaharakis, Nikola ;
Linker, Julie .
CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2016, 25 (03) :521-+